Table 1.
Comparing the clinical characteristics of the macrolide-resistant or macrolide-sensitive M. pneumoniae groups.
| Characteristic | All Patients | MRMP | MSMP | p-Value |
|---|---|---|---|---|
| n = 56 | (n = 41) | (n = 15) | ||
| Age (years) | 6.8 (5.0–9.1) | 6.3(4.7–8.8) | 7.0 (5.8–10.3) | 0.264 |
| Male:female ratio | 31:25 | 25:16 | 6:9 | 0.162 |
| Hospitalization (days) | 5 (4–6) | 5 (4–6) | 5 (5–6) | 0.774 |
| Duration of fever (days) | ||||
| Before admission | 5.0 (3.3–7.0) | 5.0 (3.5–7.0) | 5.0 (2–7.0) | 0.519 |
| Total duration | 5.0 (3.3–7.0) | 6.0 (3.5–7.5) | 5.0 (3.0–7.0) | 0.864 |
| Pulmonary infiltration, n (%) | ||||
| Bronchopneumonia | 16 (28.6) | 12 (29.3) | 4 (26.7) | 0.849 |
| Segmental/lobar pneumonia | 40 (71.4) | 29 (70.7) | 11 (73.3) | |
| Serological test, n (%) | ||||
| Initial ELISA IgM positive | 36 (64) | 27 (66) | 9 (60) | 0.686 |
| IgM seroconversion | 20 (36) | 14 (34) | 6 (40) | |
| Antibiotics, n (%) | ||||
| Macrolide, n (%) | 51(91) | 38 (93) | 13 (87) | 0.484 |
| Levofloxacin, n (%) | 2 (4) | 2 (5) | 0 | |
| Corticosteroids, n (%) | ||||
| Low-dose (1–2 mg/kg) | 46 (82) | 34 (83) | 12 (80) | 1.000 |
| High-dose (5–10 mg/kg) | 10 (18) | 7 (17) | 3 (20) | |
| Additional high-dose (10–30 mg/kg) | 2 | 2 | 0 |
MRMP: macrolide-resistant Mycoplasma pneumoniae; MSMP: macrolide-sensitive Mycoplasma pneumoniae. Continuous variables are expressed as median (interquartile range (IQR)), and categorical variables are expressed as case’s absolute number (percentage).